Evidence map›Paper›PMID 38352376›Full record

ArticlebioRxiv : the preprint server for biology2024

AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALS.

Defne A Amado, Ashley B Robbins, Alicia R Smith, Katherine R Whiteman, Guillem Chillon Bosch, Yonghong Chen, Joshua A Fuller, Aleksandar Izda, Shareen Nelson, Abigail I Dichter and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Defne A AmadoORCID 0000-0001-6202-3900
Ashley B Robbins
Alicia R Smith
Katherine R Whiteman
Guillem Chillon Bosch
Yonghong Chen
Joshua A Fuller
Aleksandar Izda
Shareen Nelson
Abigail I Dichter
Alex Mas Monteys
Beverly L Davidson
Children's Hospital of Philadelphia · US

Funding

Viral-based Therapeutic Approaches for Reversal of ALS PathologyK08NS114106 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI AMADO, DEFNE AUDREY · 2020 to 2024
$1.1M
NINDS NIH HHS K08 NS114106
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is characterized by motor neuron death due to nuclear loss and cytoplasmic aggregation of the splice factor TDP-43. Pathologic TDP-43 associates with stress granules (SGs) and downregulating the SG-associated protein Ataxin-2 (Atxn2) using antisense oligonucleotides (ASO) prolongs survival in the TAR4/4 sporadic ALS mouse model, a strategy now in clinical trials. Here, we used AAV-mediated RNAi delivery to achieve lasting and targeted

Identifiers

PMID38352376
PMCPMC10862885
OpenAlexW4391513400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.